Emcure Pharmaceuticals Soars with 24% Profit Surge

Emcure Pharmaceuticals Ltd reported a 24% increase in consolidated net profit for Q4 2026, driven by a 25.7% boost in international business sales. The company plans to sustain growth with a focus on R&D in complex injectables and biosimilars, and CEO Satish Mehta remains at the helm.

Emcure Pharmaceuticals Ltd reported a significant 24% rise in consolidated net profit, reaching Rs 243.74 crore in the fourth quarter of the fiscal year ended March 2026. The impressive results were bolstered by robust growth in the company's international business segment.

International sales surged by 25.7% year-on-year to Rs 1,493 crore, demonstrating strong expansion across markets, as noted by Emcure. Meanwhile, the domestic market experienced a more modest growth of 5.2%. Zuventus, a subsidiary undergoing team reorganisation, contributed to the softer domestic results.

CEO and MD Satish Mehta highlighted the strategic successes, referencing the international markets' momentum and the company's R&D focus on complex injectables and biosimilars. As Emcure aims for sustainable, above-industry growth, the board has approved Mehta's re-appointment and proposed a final dividend for shareholders.